0 4 CD30 CD30 NNP 5 13 ligation ligation NN 14 21 induces induce VBZ 22 29 nuclear nuclear JJ 30 42 factor-kappa factor-kappa NN 43 44 B B NNP 45 55 activation activation NN 56 58 in in IN 59 64 human human JJ 65 66 T t NN 67 71 cell cell NN 72 77 lines line NNS 77 78 . . . 80 84 CD30 CD30 NNP 85 87 is be VBZ 88 89 a a DT 90 98 recently recently RB 99 108 described describe VBN 109 115 member member NN 116 118 of of IN 119 122 the the DT 123 128 tumor tumor NN 129 137 necrosis necrosis NN 138 150 factor/nerve factor/nerve NN 151 157 growth growth NN 158 164 factor factor NN 165 173 receptor receptor NN 174 185 superfamily superfamily NN 185 186 . . . 187 189 In in IN 190 194 this this DT 195 201 report report NN 201 202 , , , 203 205 we we PRP 206 210 show show VBP 211 215 that that IN 216 225 following follow VBG 226 236 incubation incubation NN 237 239 of of IN 240 244 L540 l540 NN 245 250 cells cell NNS 251 252 ( ( ( 252 259 Hodgkin Hodgkin NNP 259 261 ’s 's POS 262 277 disease-derived disease-derived JJ 277 278 , , , 279 280 T t NN 281 290 cell-like cell-like JJ 290 291 , , , 292 297 CD30+ cd30+ JJ 298 303 cells cell NNS 303 304 ) ) ) 305 309 with with IN 310 313 the the DT 314 323 agonistic agonistic JJ 324 333 anti-CD30 anti-cd30 JJ 334 344 monoclonal monoclonal JJ 345 355 antibodies antibody NNS 356 357 ( ( ( 357 360 mAb mab NN 360 361 ) ) ) 362 365 M44 m44 NN 366 369 and and CC 370 373 M67 M67 NNP 373 374 , , , 375 378 two two CD 379 386 nuclear nuclear JJ 387 393 factor factor NN 394 395 ( ( ( 395 404 NF)-kappa NF)-kappa NNP 405 406 B B NNP 407 410 DNA DNA NNP 411 418 binding binding NN 419 429 activities activity NNS 430 434 were be VBD 435 442 induced induce VBN 443 445 in in IN 446 453 nuclear nuclear JJ 454 462 extracts extract NNS 462 463 , , , 464 466 as as IN 467 477 determined determine VBN 478 480 in in IN 481 484 gel gel NN 485 496 retardation retardation NN 497 503 assays assay NNS 503 504 . . . 505 508 The the DT 509 515 effect effect NN 516 518 of of IN 519 522 the the DT 523 526 mAb mab NN 527 534 towards towards IN 535 543 NF-kappa NF-kappa NNP 544 545 B B NNP 546 556 activation activation NN 557 560 was be VBD 561 566 rapid rapid JJ 566 567 , , , 568 570 as as IN 571 573 it it PRP 574 582 occurred occur VBD 583 589 within within IN 590 592 20 20 CD 593 596 min min NN 596 597 , , , 598 601 and and CC 602 605 was be VBD 606 615 sustained sustained JJ 616 619 for for IN 620 622 up up IN 623 625 to to TO 626 627 6 6 CD 628 629 h h NN 629 630 . . . 631 633 By by IN 634 644 comparison comparison NN 644 645 , , , 646 648 an an DT 649 664 isotype-matched isotype-matched JJ 665 673 antibody antibody NN 674 677 had have VBD 678 680 no no DT 681 687 effect effect NN 688 690 on on IN 691 699 NF-kappa NF-kappa NNP 700 701 B B NNP 702 712 activation activation NN 712 713 . . . 714 722 Moreover moreover RB 722 723 , , , 724 726 in in IN 727 732 human human JJ 733 734 T t NN 735 741 helper helper NN 742 743 ( ( ( 743 745 Th Th NNP 745 746 ) ) ) 747 753 clones clone NNS 754 766 functionally functionally RB 767 780 characterized characterize VBN 781 783 as as IN 784 789 being be VBG 790 792 of of IN 793 796 the the DT 797 801 type type NN 802 803 0 0 CD 803 804 , , , 805 809 type type NN 810 811 1 1 CD 812 815 and and CC 816 820 type type NN 821 822 2 2 CD 823 824 ( ( ( 824 826 28 28 CD 826 827 % % NN 827 828 , , , 829 830 < < SYM 831 832 1 1 CD 832 833 % % NN 834 837 und und IN 838 840 93 93 CD 840 841 % % NN 842 847 CD30+ cd30+ JJ 847 848 , , , 849 861 respectively respectively RB 861 862 ) ) ) 862 863 , , , 864 867 the the DT 868 874 extent extent NN 875 877 of of IN 878 891 CD30-mediated cd30-mediated JJ 892 900 NF-kappa NF-kappa NNP 901 902 B B NNP 903 913 activation activation NN 914 924 correlated correlate VBD 925 929 with with IN 930 933 the the DT 934 944 proportion proportion NN 945 947 of of IN 948 953 CD30+ cd30+ JJ 954 959 cells cell NNS 959 960 . . . 961 963 In in IN 964 967 all all DT 968 972 cell cell NN 973 978 lines line NNS 979 991 investigated investigate VBN 991 992 , , , 993 996 the the DT 997 1005 NF-kappa NF-kappa NNP 1006 1007 B B NNP 1008 1017 complexes complex NNS 1018 1025 induced induce VBN 1026 1035 following follow VBG 1036 1040 CD30 cd30 NN 1041 1051 engagement engagement NN 1052 1056 were be VBD 1057 1062 shown show VBN 1063 1065 to to TO 1066 1073 contain contain VB 1074 1077 p50 p50 NN 1078 1086 NF-kappa NF-kappa NNP 1087 1089 B1 B1 NNP 1089 1090 , , , 1091 1094 p65 p65 NN 1095 1099 RelA RelA NNP 1099 1100 , , , 1101 1104 and and CC 1105 1113 possibly possibly RB 1114 1119 other other JJ 1120 1133 transcription transcription NN 1134 1141 factors factor NNS 1141 1142 . . . 1143 1155 Collectively collectively RB 1155 1156 , , , 1157 1160 our our PRP$ 1161 1168 results result NNS 1169 1180 demonstrate demonstrate VBP 1181 1185 that that IN 1186 1193 nuclear nuclear JJ 1194 1207 translocation translocation NN 1208 1211 and and CC 1212 1222 activation activation NN 1223 1225 of of IN 1226 1234 NF-kappa NF-kappa NNP 1235 1236 B B NNP 1237 1241 rank rank NN 1242 1247 among among IN 1248 1251 the the DT 1252 1262 short-term short-term JJ 1263 1271 cellular cellular JJ 1272 1281 responses response NNS 1282 1290 elicited elicit VBN 1291 1300 following follow VBG 1301 1305 CD30 cd30 NN 1306 1314 ligation ligation NN 1314 1315 . . .